Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs, son of the late Steve Jobs, has shifted focus from his family name to revolutionizing biotech at his venture firm, Yosemite. During TechCrunch Disrupt, Jobs highlighted the rapid growth of his 17-member team and the potential of AI in developing blockbuster drugs. With several major pharmaceuticals losing patent protection, Yosemite is poised to capitalize on emerging opportunities. This shift underscores the growing importance of biotech innovation, especially in tackling significant health challenges like cancer.